Clinical trials: Liver Inflammation
Liver Neoplasms, Hepatitis B
Lay Health Worker Model to Reduce Liver Cancer Disparities in Asian Americans
The study was conducted between April 2013 and October 2014. In the parent study, 600 foreign-born Asian American adults 18 years of age and older were drawn from the community in the Baltimore Washington Metropolitan Area.
- Trial name
- LHWAA (NCT02760537)
- Testing
- Lay Health Worker Intervention
- Volunteers
- 232 people, healthy volunteers welcome
- Sponsor
- Thomas Jefferson University
Hepatitis C Virus Infection
UNITY 3: A Japanese Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 in Subjects With Genotype 1 Chronic Hepatitis C
The purpose of this study is to demonstrate that the proportion of treatment-naive non-cirrhotic subjects with Genotype (GT)-1b treated with Daclatasvir (DCV)/Asunaprevir (ASV)/BMS-791325 who achieve Sustained Virologic response…
- Trial name
- NCT02123654
- Testing
- Daclatasvir, Asunaprevir, DCV 3DAA
- Where
- 35 sites in Japan
- Volunteers
- 297 people
- Sponsor
- Bristol-Myers Squibb
PT-NANBH
Comparative Efficacy of Fixed-dose Combination Sofosbuvir + Ledipasvir, 8 vs. 12 Weeks in Chronic Hepatitis C Genotype 6
The primary objectives of this study are to describe the efficacy of: 1. 8-week treatment of SOF/LED for treatment-naïve, non-cirrhotic, HCV genotype 6 2. 12-week treatment of SOF/LED for all other HCV-6 populations
- Trial name
- NCT02480166
- Testing
- 8 weeks SOF/LED, 12 weeks SOF/LED
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- Stanford University
Hepatitis C Infection, Viruses
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
The purpose of this study is to test the safety and efficacy of Civacir® to prevent the recurrence of Hepatitis C Virus (HCV) after liver transplant.
- Conditions
- Hepatitis C Infection, Viruses, Hepatocellular Carcinoma, Hepatitis, Viral, Human
- Trial name
- NCT01804829
- Testing
- Civacir® 10%
- Where
- 23 sites in United States
- Volunteers
- 80 people
- Sponsor
- Biotest Pharmaceuticals Corporation
Chronic Hepatitis B
A Control Study to Evaluate The Efficacy And Safety of Ozone-therapy in Chronic Hepatitis B
The purpose of this study is to investigate the efficacy and safety of medical ozone in treatment of chronic hepatitis B patients.
- Trial name
- NCT01887275
- Testing
- medical ozone therapy with humares, conventional interferon-α
- Where
- China
- Volunteers
- 439 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Hepatitis B, Chronic
A Study of Pegasys Monotherapy in Patients With Chronic Hepatitis B Who Have Participated in Previous Studies
In this open-label multicenter study the long-term effect of Pegasys monotherapy on pharmacodynamic HBV-related markers will be investigated in patients with chronic hepatitis B.
- Trial name
- NCT00962975
- Testing
- peginterferon alfa-2a [Pegasys]
- Where
- 6 sites in United States, New Zealand and 2 more
- Volunteers
- 29 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C
Screening Hepatitis Positive Women for Congenital Anomalies
Hepatitis C virus is one of the virulent viruses
- Trial name
- NCT03980301
- Testing
- ultrasound
- Where
- Egypt
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Aljazeera Hospital
Diphtheria, Tetanus
Assess Immune Response Following Primary Vaccination With Tritanrix™-HepB Vaccine Mixed With 3 Formulations of Hib-MenAC Vaccine to Infants
To compare three formulations of Hib-MenAC vaccines mixed with Tritanrix™-HepB vaccine with that of Tritanrix™-HepB vaccine concomitantly administered with GSK Biologicals' Hiberix™ vaccine and Tritanrix™-HepB vaccine mixed with…
- Conditions
- Diphtheria, Tetanus, Pertussis, Hepatitis B
- Trial name
- NCT00291967
- Testing
- DTPw-HBV/Hib-MenAC conjugate vaccine
- Where
- Philippines
- Volunteers
- 525 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatitis C
Immune Monitoring of Hepatitis C Under DAA Therapy
Direct acting antivirals offer a new opportunity to monitor the immune response in Hepatitis C infection. In this study cytokine markers will be measured during therapy up to time point SVR 12 an correlated to clinical Parameters…
- Trial name
- IMHC (NCT02904603)
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- University of Regensburg
Hepatitis B
Simvastatin for the Treatment of Chronic Hepatitis B
The investigators have shown robust in vitro anti-hepatitis B activity of simvastatin alone and synergistic activity with all four FDA-approved anti-hepatitis B oral drugs tested.
- Trial name
- NCT00994773
- Testing
- Simvastatin, Tenofovir, Entecavir
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Bader, Ted, M.D.
Hepatitis C, Major Depressive Disorder
A Health Intervention to Prevent Depression Hepatitis C Patients
Interferon-alpha (IFN-α) is an efficacious treatment for Hepatitis C (HPC); however, IFN-α treatment results in a significant increase in depressive symptoms.
- Trial name
- NCT01890083
- Testing
- Exercise, Health Education
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Texas Southwestern Medical Center
Non Small Cell Lung Cancer, Hepatitis B
Clinical Pharmacokinetics of TKIs in Chinese Patients of Hepatitis B (HBV)
The study will explore the characteristics in clinical pharmacokinetics of gefitinib, erlotinib,afatinib,osimertinib, crizotinib, apatinib, icotinib in Chinese patients of Non-small-cell lung cancer and hepatitis B.
- Trial name
- NCT03680183
- Testing
- Entecavir 1Mg Oral Tablet
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Liver Fibrosis
Hydronidone for the Treatment of Liver Fibrosis Associated with Chronic Viral Hepatitis B Phase 3 Trial.
This study was a randomized, double-blind, placebo-controlled, entecavir basic treatment, multicentre clinical study. The main objective of this study was to confirm the efficacy and safety of hydronidone in the treatment of…
- Trial name
- NCT05115942
- Testing
- Hydronidone capsules
- Where
- 44 sites in China
- Volunteers
- 248 people
- Sponsor
- Beijing Continent Pharmaceutical Co, Ltd.
Chronic Hepatitis C
Effect of Teleprevir in Triple Therapy on Intrahepatic Immunological Mechanisms
Chronic hepatitis C infection (HCV) is a disease that affects worldwide about 170 million people. The previous standard of care therapy of chronic HCV patients consists of pegylated-IFN-α combined with ribavirin, and results in…
- Trial name
- ETIM (NCT01641094)
- Where
- 2 sites in Netherlands
- Volunteers
- 20 people
- Sponsor
- Foundation for Liver Research
Hepatitis C, Chronic
A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection
The purpose of this study is to evaluate the safety and efficacy of co-administration of ABT-450 (also known as paritaprevir) with ritonavir (ABT-450/r) and ABT-267 (also known as ombitasvir) in adults with chronic hepatitis C…
- Trial name
- PEARL-I (NCT01685203)
- Testing
- ABT-450/r, ABT-267, Ribavirin (RBV)
- Volunteers
- 316 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Self Efficacy, Hepatitis C
Y- Shaped Pegylated Interferon (YPEG-IFNα-2a) Plus Ribavirin in Egyptian Patients With Untreated Chronic Hepatitis C
The objective is to assess the efficacy, dosing, safety and tolerance of Y- shaped pegylated interferon (YPEG-IFNα-2a) plus ribavirin in Egyptian patients with chronic hepatitis C and with no prior treatment for hepatitis C virus…
- Trial name
- NCT01327729
- Testing
- pegylated interferon alpha 2a YPEG-IFN α-2a 180mcg
- Where
- Egypt
- Volunteers
- 300 people
- Sponsor
- BioGeneric Pharma
HBe Negative Chronic Hepatitis B, Hepatitis B Viral Infection
ANRS HB 05 Multicenter Study Evaluating Efficacy and Safety of Clevudine Monotherapy Versus Tenofovir Monotherapy Versus Combination Therapy of Clevudine and Tenofovir for 96 Weeks in HBeAg Negative Patients With Chronic Hepatitis B, naïve to Anti-VHB Therapy
For chronic HBV infection, an optimal pharmacological agent to promote recovery from chronic HBV infection would be one that inhibits HBV DNA polymerase, combined with the clearence from the liver of cccDNA to block HBV…
- Trial name
- NCT00823342
- Testing
- CLEVUDINE IN ASSOCIATION TENOFOVIR
- Where
- France
- Volunteers
- 150 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
Hepatitis C, Chronic, Cirrhosis, Decompensated
Effects of Harvoni in Patients With Decompensated Cirrhosis Due to Hepatitis C Genotype 1 Infection
There are now several licensed drug treatments for patients with HCV infection. These medications have been shown to be very effective in getting rid of the virus in patients with HCV infection including those with early stages…
- Trial name
- NCT02597166
- Testing
- Ledipasvir/Sofosbuvir
- Where
- Canada
- Volunteers
- 14 people
- Sponsor
- University Health Network, Toronto
Hepatitis C
Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study)
The purpose of the study is to determine whether the combination of Daclatasvir (DCV), Asunaprevir (ASV), BMS-791325 and Sofosbuvir is effective and safe in treating Hepatitis-C virus.
- Trial name
- FOURward (NCT02175966)
- Testing
- DCV/ASV/BMS-791325, Ribavirin, Sofosbuvir
- Where
- 7 sites in United States
- Volunteers
- 35 people
- Sponsor
- Bristol-Myers Squibb
HCV Coinfection, HIV-1 Infection
Boceprevir in HIV-HCV Coinfected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin
The majority of Human immunodeficiency Virus (HIV)/Hepatitis C Virus (HCV) co-infected patients are non responders after 48 weeks of the current standard-of-care with Peg-Interferon/Ribavirin.
- Trial name
- BocepreVIH (NCT01335529)
- Testing
- Boceprevir, Peg-interferon alfa 2b and Ribavirin
- Where
- France
- Volunteers
- 69 people
- Sponsor
- ANRS, Emerging Infectious Diseases
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.